Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Thermo Fisher Scientific    TMO

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Exclusive: Thermo Fisher weighs Life Tech takeover-sources

01/29/2013 | 09:47pm EST

NEW YORK (Reuters) - Thermo Fisher Scientific Inc (>> Thermo Fisher Scientific Inc.) is considering making an offer for Life Technologies Corp (>> Life Technologies Corp.), the biomedical laboratory equipment maker that is exploring a potential sale, three people familiar with the matter said on Tuesday.

NEW YORK (Reuters) - Thermo Fisher Scientific Inc (>> Thermo Fisher Scientific Inc.) is considering making an offer for Life Technologies Corp (>> Life Technologies Corp.), the biomedical laboratory equipment maker that is exploring a potential sale, three people familiar with the matter said on Tuesday.

Thermo Fisher, the world's largest maker of laboratory equipment and scientific instruments, is one of the parties that have held discussions with Life Technologies about a potential deal, said the sources, who asked to be anonymous because the talks are confidential.

Private equity firms KKR & Co LP (>> KKR & Co. L.P.), Blackstone Group LP (>> The Blackstone Group L.P.), Bain Capital LLC and TPG Capital LP are also interested in buying Carlsbad, California-based Life Technologies, which has a $10.7 billion market capitalization, the sources said.

Waltham, Massachusetts-based Thermo Fisher has a market value of around $25 billion.

Talks with the potential buyers are at an early stage and may not lead to a transaction, the sources said.

Thermo Fisher and Life Technologies officials declined to comment. Representatives of the private equity firms declined to comment or did not respond to requests for comment.

If completed, the purchase by Thermo Fisher of Life Technologies would mark its biggest acquisition since 2006, when the company was created through the $12.8 billion merger of Thermo Electron Corp with Fisher Scientific International Inc.

The U.S. government's efforts to curb spending to fix its budget deficit has resulted in a lull in government-sponsored medical research, hurting companies that make life-science tools. Thermo Fisher's response so far has been to expand in emerging markets such as China.

Life Technologies, which makes genetic testing equipment and products used in biotechnology development, said on January 18 that its board has hired Deutsche Bank Securities (>> Deutsche Bank AG) and Moelis & Company to assist in its "annual strategic review". Deutsche Bank and Moelis declined to comment.

Given the sheer size of a potential leveraged buyout, private equity bidders are expected to team up as the sale process advances, Reuters reported previously.

"Fitch thinks that there is a lack of an obvious business strategy behind a leveraged buyout transaction, such as cost cutting opportunities," analysts from the credit rating agency wrote in a note on Tuesday.

"An acquisition by a strategic interest could be more likely given opportunities for cost synergies, coupled with the attractive growth potential of the company's next-generation DNA sequencing assets," Fitch added.

Thermo Fisher serves more than 350,000 customers in pharmaceutical and biotechnology companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies.

Analysts have previously suggested that Thermo Fischer may have the financial firepower to buy Life Technologies, provided it sees the rationale for an acquisition of the entire company.

"We believe Thermo may be interested in the recurring revenue and synergy potential of the research consumables business (of Life Technologies) as well as solid growth of the applied sciences business," UBS analysts wrote in a note this week.

"(Thermo) management has historically not been interested in playing in the next-generation DNA sequencing market, making the ion torrent business less attractive," they added.

(Reporting by Soyoung Kim and Greg Roumeliotis in New York; Editing by Matt Driskill)

By Soyoung Kim and Greg Roumeliotis


© Reuters 2013
Stocks mentioned in the article
ChangeLast1st jan.
DANAHER CORPORATION 0.02% 236.75 Delayed Quote.6.58%
DEUTSCHE BANK AG -3.69% 9.627 Delayed Quote.7.58%
GENERAL ELECTRIC COMPANY -2.83% 11.33 Delayed Quote.4.91%
TEAM, INC. -7.86% 10.9 Delayed Quote.0.00%
THE LEAD CO., INC. 1.69% 842 End-of-day quote.0.24%
THERMO FISHER SCIENTIFIC 1.25% 503.14 Delayed Quote.6.68%
All news about THERMO FISHER SCIENTIFIC
01/15Wells Fargo, Exxon Mobil fall; Thermo Fisher, Axon rise
AQ
01/15THERMO FISHER SCIENTIFIC : Extends SARS-CoV-2 GlobalAccess Sequencing Program to..
AQ
01/15THERMO FISHER SCIENTIFIC : Completes Henogen Buyout for Nearly $880 Million
MT
01/15THERMO FISHER SCIENTIFIC : Buys Viral Vector Manufacturing Business From Novasep..
DJ
01/15THERMO FISHER SCIENTIFIC : Acquires Viral Vector Manufacturing Business from Nov..
PR
01/12THERMO FISHER SCIENTIFIC : Credit Suisse Adjusts Thermo Fisher Scientific's Pric..
MT
01/11SEER : Secures Commercial Rights For Thermo Fisher's Orbitrap Mass Spectrometry ..
MT
01/11THERMO FISHER SCIENTIFIC INC. : Results of Operations and Financial Condition (f..
AQ
01/08Credit Suisse Says Positive Developments in Healthcare 'Underappreciated'; To..
MT
01/08Coronavirus variants may lead to false negative results with molecular tests ..
RE
More news
Financials (USD)
Sales 2020 30 963 M - -
Net income 2020 6 076 M - -
Net Debt 2020 12 168 M - -
P/E ratio 2020 32,9x
Yield 2020 0,17%
Capitalization 199 B 199 B -
EV / Sales 2020 6,83x
EV / Sales 2021 6,15x
Nbr of Employees 75 000
Free-Float 90,6%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | TMO | US8835561023 | MarketScreener
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 525,45 $
Last Close Price 503,14 $
Spread / Highest target 23,2%
Spread / Average Target 4,44%
Spread / Lowest Target -23,7%
EPS Revisions
Managers and Directors
NameTitle
Marc N. Casper Chairman, President & Chief Executive Officer
Mark P. Stevenson Chief Operating Officer & Executive Vice President
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Scott M. Sperling Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERMO FISHER SCIENTIFIC6.68%199 412
DANAHER CORPORATION6.58%168 182
INTUITIVE SURGICAL, INC.-4.85%91 508
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.3.75%82 922
SIEMENS HEALTHINEERS AG3.86%56 444
ILLUMINA, INC.1.72%54 947